Jacqueline Carbone
Nurse Practitioner · Denver, CONPI 1386194942
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.3% of the total across 259 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 34 manufacturers reported payments, led by AbbVie at 25.0% of the total. Among nurse practitioner clinicians in CO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 259 payments — averaging $27.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Axsome Therapeutics, Inc.$880
- Pfizer$737
- Amgen$574
- Biohaven Pharmaceutical Holding Company Ltd.$303
- Biohaven Pharmaceuticals, Inc.$278
- plus $2K from 28 others
What the payments were for
- Speaking & faculty fees$2504%
- Food & beverage$6,73196%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 72 | $1,749 |
| Axsome Therapeutics, Inc. | 17 | $880 |
| Pfizer | 48 | $737 |
| Amgen | 14 | $574 |
| Biohaven Pharmaceutical Holding Company Ltd. | 16 | $303 |
| Biohaven Pharmaceuticals, Inc. | 16 | $278 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $271 |
| Vanda Pharmaceuticals Inc. | 4 | $240 |
| Collegium Pharmaceutical, Inc. | 12 | $224 |
| Medtronic | 2 | $221 |
| GRT US Holding, Inc. | 5 | $181 |
| Idorsia Pharmaceuticals US Inc | 4 | $161 |
| Teva Pharmaceuticals USA, Inc. | 3 | $143 |
| Indivior Inc. | 7 | $132 |
| Nevro Corp. | 1 | $126 |
| Novo Nordisk | 3 | $110 |
| Scilex Pharmaceuticals Inc. | 6 | $96 |
| Almatica Pharma LLC | 4 | $90 |
| Tonix Medicines, Inc. | 1 | $84 |
| Lilly USA, LLC | 5 | $75 |
| Alkermes, Inc. | 2 | $43 |
| Viiv Healthcare Company | 2 | $35 |
| Impel Pharmaceuticals Inc. | 1 | $28 |
| Jazz Pharmaceuticals Inc. | 1 | $27 |
| Biogen | 1 | $25 |
| Otsuka America Pharmaceutical, Inc. | 1 | $24 |
| Biodelivery Sciences International, Inc. | 1 | $22 |
| Otto Bock Healthcare LP | 1 | $20 |
| Ironshore Pharmaceuticals Inc. | 1 | $19 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $18 |
| Ultragenyx Pharmaceutical Inc. | 1 | $17 |
| Vertex | 1 | $16 |
| Eisai Inc. | 1 | $12 |
| Redhill Biopharma Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,993 in reported general payments places this provider in the 95th percentile of 1,384 nurse practitioner providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Xtampza ErOxycodone Myristate | 100 | $99,440 |
| OxycontinOxycodone Hcl | 57 | $58,799 |
| VraylarCariprazine Hcl | 24 | $30,892 |
| ZtlidoLidocaine | 28 | $30,447 |
| Nurtec OdtRimegepant Sulfate | 17 | $18,659 |
| Nucynta ErTapentadol Hcl | 26 | $17,366 |
| NucyntaTapentadol Hcl | 13 | $13,733 |
| Fentanyl | 101 | $12,080 |
| AuvelityDextromethorphan Hbr/Bupropion | 17 | $11,515 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 25 | $10,033 |
| Oxycodone Hcl | 464 | $9,677 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 13 | $9,045 |
| Lidocaine | 39 | $7,216 |
| LinzessLinaclotide | 12 | $6,213 |
| CymbaltaDuloxetine Hcl | 11 | $6,100 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Xtampza Er, Nucynta Er, Nucynta | $224 | $130,539139 claims |
| AbbVieVraylar, Linzess | $1,749 | $37,10536 claims |
| Scilex Pharmaceuticals Inc.Ztlido | $96 | $30,44728 claims |
| PfizerNurtec Odt | $737 | $18,65917 claims |
| Axsome Therapeutics, Inc.Auvelity | $880 | $11,51517 claims |
| Lilly USA, LLCCymbalta | $75 | $6,10011 claims |
| Redhill Biopharma Inc.Movantik | $11 | $5,55913 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,384 nurse practitioner providers in Colorado.
Other nurse practitioner in Denver
- Christina ProulxDenver$28K
- Jose Diaz LeoDenver$24K
- Lolanda McBrideDenver$20K
- Cori FratelliDenver$15K
- Leslie HindsDenver$9K
- Rebecca AndrieDenver$8K
- Nahid Kuseh Kalani YazdDenver$8K
- Amber Whitton-SmithDenver$7K
- Stephanie WyttenbachDenver$7K
- Dana HammondsDenver$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.